Resvita Bio develops and manufactures engineered probiotics for use in treatment if skin related diseases including cancer.
Resvita Bio has raised $2.0M in total funding. The most recent round was Grant. The last funding was announced in September 2024.
Resvita Bio's investors include Pioneer Fund, National Institutes of Health, National Institute of Allergy and Infectious Diseases.
Resvita Bio is headquartered in Berkeley, United States.
Resvita Bio develops and manufactures engineered probiotics for use in treatment if skin related diseases including cancer.
Resvita Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Resvita Bio — Funding & Investors." VCBacked, September 24, 2024, https://www.vcbacked.co/company/resvita-bio. Accessed July 20, 2026.
VCBacked. (2024). Resvita Bio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/resvita-bio
{{cite web |title=Resvita Bio — Funding & Investors |url=https://www.vcbacked.co/company/resvita-bio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated